The safety of pharmacological therapies for gastrointestinal conditions encountered during pregnancy.
Properly assessing the safety of pharmacological therapies for gastrointestinal conditions encountered during pregnancy is a challenge on account of both the often limited controlled data available and the potentially confounding effect of the underlying disorders requiring treatment on fetal outcomes. Here, the available data with regard to gastrointestinal disorders specific to pregnancy, those that may be precipitated or exacerbated by pregnancy and those that may be pre-existing or arise concurrently during pregnancy are reviewed.
Almeida
John A
JA
The Prince of Wales Hospital of New South Wales, Gastrointestinal and Liver Unit, Barker Street, Randwick 2031, New South Wales, Sydney, Australia.
Riordan
Stephen M
SM
D000818:Animals; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000378:metabolism
D005765:Gastrointestinal Agents